Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Nephropathy, Diabetes
Interventions: Atrasentan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Laguna Hills, California • Santa Monica, California • Evergreen Park, Illinois + 6 more

Conditions: Gestational Diabetes
Interventions: Soy Group (Soy Protein + Isoflavones), Control Group (Minimize Soy Intake); Dietary Supplement
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lactation, Other Disorders of Bone Density and Structure, Endocrine; Complications
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Ketoacidosis
Interventions: intravenous fluid treatment; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions: Metyrapone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Polycystic Ovary Syndrome, Vitamin D Deficiency
Interventions: Vitamin D3; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 16 Years to 48 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Kidney Disease, Metabolic Acidosis
Interventions: Sodium bicarbonate, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: The Bronx, New York • Cleveland, Ohio

Conditions: Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions: observational study; Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Diabetes Mellitus, Hemodialysis Complication, Cardiovascular Complication, Quality of Life
Interventions: Tennant Biomodulator ®; Device
Lead sponsor: Hamad Medical Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Nephropathy
Interventions: Pyridoxamine Dihydrochloride, Placebo; Drug
Lead sponsor: NephroGenex, Inc.; Industry
Eligibility: 25 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions: AP301, AP301 Low Dose; Drug
Lead sponsor: Alebund Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more

Conditions: Gestational Diabetes
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Michael Mauer, MD; Individual
Eligibility: 18 Years to 60 Years
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1981 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gout, Chronic Kidney Disease (CKD)
Interventions: Lesinurad, XOI, Placebo, colchicine, corticosteroids; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 70
States / cities: Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more

Conditions: Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions: Hydrocortisone, dexamethasone, Cosyntropin, rhCG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 16 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Multi-Organ Denervation Gemini System; Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more

Conditions: Insulin Resistance, Hypertriglyceridemia, Diabetes, Hepatic Steatosis
Interventions: low-fat diet ( Still recruiting ), Diet; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions: Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention; Dietary Supplement · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes During Pregnancy
Interventions: High-Protein Beverage (Genius Gourmet Sparkling Protein Water), Standard Clear Liquid Diet, Continuous Glucose Monitoring (Abbott Freestyle Libre); Dietary Supplement · Other · Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Endometrial Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 8
States / cities: Houston, Texas

Conditions: Painful Diabetic Neuropathy (PDN)
Interventions: EPT, Drug Placebo Administration, C; Other · Drug
Lead sponsor: Analgesic Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Obesity, Diabetes, Gestational
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: Not listed
Enrollment: 2,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cardiovascular-kidney-metabolic Syndrome, Diabete Type 2, Chronic Kidney Disease, Heart Failure
Interventions: Real-Time EHR Prompts and Audit-and-Feedback Reports; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pleasanton, California

Search by objective public record fields.

Atrasentan Spermatogenesis and Testicular Function

Soy Supplementation and Gestational Diabetes

Longitudinal Lactation Bone Density Study

Cerebral Edema in Pediatric Diabetic Ketoacidosis

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Alkali Therapy in Chronic Kidney Disease

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility

Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Fetal Cardiac Function Parameters and HbA1c As Screening for Gestational Diabetes Mellitus

Studies of Organ Transplantation in Animals and Man

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

SPYRAL GEMINI Pilot Study

Novel Therapies for Metabolic Complications of Lipodystrophies

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas

Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies

Metabolism, Breastmilk, and Microbiome

SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome